 |
|
  |
        |
 |
|
|
|||||
|
Dr.
Weintraub has more than 30 years experience in a biomedical research career
that has focused on molecular, cellular, clinical and therapeutic aspects
of glycoprotein hormones, related growth factors, thyroid hormone and
their receptors. He is the author of over 300 scientific Dr. Weintraub obtained his BA from Princeton University magna cum laude where he was elected to Phi Beta Kappa and his MD from Harvard University cum laude where he was elected to Alpha Omega Alpha. His postdoctoral clinical and basic science training were at Harvard and the National Insitutes of Health and he later served as Assistant Professor at Harvard. In 1972 he became the first Director of the NIH Endocrinology Training Program and later Chief of its Molecular and Cellular Endocrinology Branch, positions he held until 1995. In both these positions he helped train a generation of leading international academic and clinical endocrinologists. From 1996- 2001 he was Professor of Medicine at the University of Maryland at Baltimore, Chief of the Laboratory of Molecular Endocrinology of the Institute of Human Virology of the University of Maryland Biotechnology Institute and Director of the Thyroid Cancer Program of the Greenebaum Cancer Center. He has received numerous international awards and lectureships, is a member of many scientific research organizations, served on several journal editorial boards as well as on several advisory committees to NIH and various universities. He has also served on the Council of the Endocrine Society and the American Thyroid Association as well as President of the Maryland Endocrine Society.
Mariusz
W. Szkudlinski, MD, PhD Dr.
Szkudlinski has more than twenty years of experience in biomedical research.
He is an author or co-author of more than 70 scientific papers, reviews,
book chapters, patents and patent applications. His work includes a landmark
paper entitled "Engineering human glycoprotein Dr. Szkudlinski obtained his M.D. and Ph.D. degrees from the University of Lodz in Poland. His postdoctoral training included the Institute of Hormone and Fertility Research in Hamburg (Germany) and the National Institutes of Health in Bethesda. Prior to co-founding Trophogen, Inc., Dr. Szkudlinski was an Assistant Professor and Chief of Protein Engineering Section in the Laboratory of Molecular Endocrinology in the University of Maryland. In that capacity, he was responsible for several structure-function and protein engineering projects within the Laboratory of Molecular Endocrinology and the Division of Basic Science of the Institute of Human Virology (UMBI). He has received numerous awards for excellence in research, presented his work at many national and international meetings, lectured at various universities, including Harvard Reproductive Science Center. He has trained numerous students and postdoctoral fellows. He serves as a reviewer in several leading journals and was invited to several national scientific panels. He is currently a member of the American Thyroid Association Research Committee and several other biomedical organizations including Endocrine Society and American Society for Biochemistry and Molecular Biology.
Valerie Fremont, PhD Safety Officer
Vladimir Wolf, PhD Information Technology Officer Dr. Wolf obtained his Ph.D. degree in Molecular biology from the University of Bern in Switzerland where his work was awarded by the travel grant to present at an AACR meeting in 1997. His doctoral thesis was focused on early events in apoptosis of mammary epithelia. The malfunction of which often leads to cancer development. The gene he helped to discover and analyze turned out to be an important inhibitor of Wnt signaling pathway. This pathway is important in early embryonic development as a tissue polarity and cell fate determining factor, as a survival factor and differentiation blocker in blood circulating stem cells, it is involved in angiogenesis and vascularisation, arthritis, etc. During his post-doctoral training at National Cancer Institute he contributed to a better understanding of the biochemistry of inhibition of Wnt/Frizzled receptor binding by secreted Frizzled Related Proteins. Subsequent to his postdoc training, Dr. Wolf continued working as a FTE research fellow in the same lab for additional 2 years. After he left NCI and shortly utilized his experiences in studying ligand/receptor interactions in research of dopamine/dopamine transporter interactions in the Laboratory of Neurochemistry at Georgetown University. In October 2004, Dr. Wolf joined Trophogen.
Elena
Glotser,
Karen Dugard, BS
Ms. Dugard was with the USDA’s Food Safety and Inspection Service as a management analyst before switching to a career as an accountant with the Department of Commerce’s Office of the Secretary and later with the USDA’s Economic Management Service. She has been in the private sector since 1991, is a former business owner, and has 15 years of experience in office management and bookkeeping. She holds a Bachelor of Science degree in Animal Science from the University of Maryland.
|
|
papers,
reviews and book chapters. In addition has several issued and pending
patents related to the cloning of the human TSH beta subunit, development
of recombinant TSH, and development of superactive analogs of TSH, gonadotropins
and related cystine knot growth factors. He is well known for his basic
science work related to pituitary and recombinant TSH synthesis, glycosylation
and action, affinity chromatography as well as clinical aspects of syndromes
of inappropriate TSH secretion. In addition he was among the first to
recognize and define the clinical and molecular aspects of thyroid hormone
resistance, TSH- producing pituitary tumors and ectopic production of
placental hormones and free subunits by various tumors. He is particularly
recognized for his role as coinventor, codeveloper and a leading investigator
in the international clinical trials of recombinant TSH, approved by the
FDA in 1998 for the diagnosis of thyroid cancer, which has revolutionized
the approach world -wide to that disease.
hormone superactive analogs" that has been recognized as "the
advent of super hormone drugs" and an important achievement in protein
engineering (Analysis Research News, Nature Biotechnology 14, 1224, 1996;
Molecular Biology and Biotechnology, 4th Edition, The Royal Society of
Chemistry, London 2000). In addition to his design of the first superactive
analogs of glycoprotein hormones and VEGF, Dr. Szkudlinski contributed
to better understanding of changes in the bioactivity of glycoprotein
hormones during evolution and the development of novel strategies in the
design of therapeutically useful cystine-knot growth factor superactive
analogs. His previous work also includes studies on prostaglandins, local
renin-angiotensin system, production and characterization of recombinant
TSH isoforms, development of various bioassays as well as elucidation
of the role of carbohydrate chains in TSH activity, metabolic clearance
and organ distribution. Dr. Szkudlinski and his colleagues have identified
novel domains in TSH and gonadotropins important in hormone-receptor interaction,
designed long-acting analogs based on site-specific pegylation, glycosylation
or subunit linking,, and more recently provided new important insights
into the mechanism of hormone dependent and independent receptor activation.
back
to top